Which drug is a T cell inhibitor used in the treatment of KCS?

The choice of Optimmune (cyclosporine) 0.2% as a T cell inhibitor in the treatment of Keratoconjunctivitis Sicca (KCS) is based on its specific mechanism of action. Cyclosporine is an immunosuppressive agent that primarily inhibits T cell activation and proliferation. In the context of KCS, which is often linked to an autoimmune component involving T cells attacking the lacrimal glands leading to reduced tear production, the use of cyclosporine serves to modulate the immune response, thereby helping to restore tear production and alleviate the symptoms associated with the condition.

In contrast, Prednisolone is a corticosteroid that reduces inflammation but does not specifically target T cells in the same way that cyclosporine does. It can provide symptomatic relief but may not be as effective in addressing the underlying immune-mediated aspect of KCS. Phenylephrine is an adrenergic agonist primarily used as a vasoconstrictor and does not relate to T cell modulation or the treatment of KCS. Timolol, a beta-blocker, is typically utilized in managing intraocular pressure in glaucoma patients and does not have a role in treating KCS.

Therefore, Optimmune (cycl